^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Davanat (galactomannan)

i
Other names: GM-CT-01
Associations
Trials
Company:
Galectin Therap
Drug class:
Galectin inhibitor
Related drugs:
Associations
Trials
2ms
Pathways in the brain, heart and lung influenced by SARS-CoV-2 NSP6 and SARS-CoV-2 regulated miRNAs: an in silico study hinting cancer incidence. (PubMed, Cardiooncology)
This study highlights probable hub genes, drugs targeting them, and associated pathways perturbed by SARS-CoV-2 NSP6. Galectin3 (LGALS3) upregulated in both heart and brain after COVID-19 infection is reported to be influencing all the ten hallmarks of cancer. Our bioinformatics and systems study hints probable effect of COVID-19 infection in cancer incidence and warrants in-depth studies for present scenario of long and recurrent COVID-19.
Journal
|
CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • EGF (Epidermal growth factor) • LGALS3 (Galectin 3) • TGFB1 (Transforming Growth Factor Beta 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • ATP6AP1 (ATPase H+ Transporting Accessory Protein 1) • CANX (Calnexin) • CCNA1 (Cyclin A1) • CCNB1 (Cyclin B1) • LAMP2 (Lysosomal Associated Membrane Protein 2)
|
Erbitux (cetuximab) • Ibrance (palbociclib) • lapatinib • doxorubicin hydrochloride • irinotecan • methotrexate • Tomudex (raltitrexed) • Davanat (galactomannan)
4ms
Davanat-Mimetic Galactomannan and Its Sulfated Derivative: Structure and Antitumor Effects against Melanoma. (PubMed, Biomacromolecules)
Although in vitro lymphocyte proliferation was not observed, CD3+ cells increased in the metastatic lungs. These results suggest GGH and GGHS as immunostimulatory agents, with GGH as potential melanoma adjuvant therapy.
Journal
|
LGALS1 (Galectin 1)
|
Davanat (galactomannan)
3years
Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
Plant-derived carbohydrates GM-CT-01 and GR-MD-02 were used to inhibit extracellular Galectin-1/-3 binding to BCP-ALL cells in co-culture with stromal cells. Treatment with these compounds attenuated migration of the BCP-ALL cells to stromal cells and sensitized human BCP-ALL cells to vincristine and the targeted tyrosine kinase inhibitor nilotinib...Taken together, our results indicate a complicated joint contribution of Galectin-1 and Galectin-3 to BCP-ALL survival, with different roles for endogenous and stromal produced Galectins. These data indicate it will be important to efficiently block both extracellular and intracellular Galectin-1 and Galectin-3 with the goal of reducing BCP-ALL persistence in the protective bone marrow niche during chemotherapy.
Journal
|
LGALS1 (Galectin 1) • LGALS3 (Galectin 3) • ST6GAL1 (ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1)
|
Tasigna (nilotinib) • vincristine • Davanat (galactomannan) • belapectin (GR-MD-02)